Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

  Homepage
Continue on the current website:  

 

Neuro Service Line

Explore AI apps curated for multiple Neurological pathologies/conditions on Calantic platform, featuring Ischemic Stroke and Neurodegenerative disease.

Neuro

    *Currently not available within the Calantic Viewer. Separately distributed by Bayer.

    • CINA has CE marking and risk class I.
    • CINA-ASPECTS has CE marking and risk class I
    • e-CTA has CE marking (CE0197) and risk class IIa
    • e-ASPECTS has CE marking (CE0197) and risk class IIa
    • e-CTP has CE marking (CE0197) and risk class IIa
    • mdbrain has CE marking (CE0123) and risk class IIb.
    • icobrain ct and icobrain mr have CE marking (CE1639) and risk class Im.
    • icobrain mr has CE marking (CE1639) and risk class Im.
    • IB Clinic has CE marking and risk class I.
      1. Instructions for Use CINA, software version 1.0
      2. Instructions for Use CINA-ASPECTS, software version 1.4
      3. Instructions for Use e-CTA, software version 11.2
      4. Instructions for Use e-ASPECTS, software version 11.2
      5. Instructions for Use e-CTP, software version 11.2
      6. Instructions for Use mdbrain, software version 4.6
      7. Instructions for Use icobrain ct, software version 6.1
      8. Instructions for Use icobrain mr, software version 5.8
      9. Instructions for Use IB Clinic, software version 2.0
      Request a demo wave top

      Request a demo and discover how to

      • Centralize your AI apps on one platform
      • Deploy service lines tailored to specific body regions/pathologies
      • Integrate Calantic into your existing health information technology system
      Get a Demo
      Request a demo

      PATHOLOGY

      Covid-19

      Vendor

      Nanoxai

      APP icolung ct

      DESCRIPTION

      icolung ct supports automatic labeling, visualization and volumetric quantification of segmentable lung structures from non-contrast enhanced chest CT. It also measures percentage of abnormality in each lobe and in total lungs.5

      PATHOLOGY

      COPD & ILD

      Vendor

      Nanoxai

      APP VIDA Insights

      DESCRIPTION

      VIDA Insights provides quantitative chest CT analysis used to profile and manage patients with/or at-risk of lung disease. It provides a flag of lung density abnormalities that may be indicative of emphysema (COPD) or interstitial lung abnormalities (ILAs).4

      Not all offerings are available in all market. For availability specific to your country please contact your local Bayer representative.

      Contraindications: HealthPNX+ device and HealthCXR device should not be used to analyze scans of patients under 18 years old, scans which are not AP or PA chest x-ray, scans with severe missing image artifacts, scans missing parts of the chest cavity or scans that are unnaturally monochrome in nature (too black or too white). Non-standard scans may skew analysis results, and if such scans are sent to the HealthPNX+device or HealthCXR device, physicians should disregard results from the scans. No other contraindications are described.

      1. Instructions for Use HealthPNX+ V2.0: Pneumothorax Triage Device, software version 2.0
      2. Instructions for Use HealthCXR Triage Device, software version 1.0
      3. Instructions for Use ClearRead CT, software version 3.6.0 - 5.5.0
      4. Instructions for Use icolung ct, software version 0.7.2